Skip to main content
Top
Published in: Rheumatology International 2/2015

01-02-2015 | Original Article

Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial

Authors: Maurizio Rossini, Silvano Adami, Elena Fracassi, Ombretta Viapiana, Giovanni Orsolini, Maria Rosaria Povino, Luca Idolazzi, Davide Gatti

Published in: Rheumatology International | Issue 2/2015

Login to get access

Abstract

Aim of this study was to evaluate the efficacy and tolerability of intra-articular (IA) clodronate, compared to saline solution, in patients with symptomatic knee osteoarthritis (KOA). In this double-blind phase 3 randomized clinical trial, patients were randomized to receive once weekly IA injection of 2 mg clodronate or placebo for 4 weeks with 12 weeks of follow-up. The primary objective was the sum of spontaneous, on passive movement, and at digital pressing pain relief assessed by visual analogue score (VAS) of 0–100 at 5 weeks after the final injection. Improving in Western Ontario MacMaster (WOMAC) scale, Lequesne index, consumption of acetaminophen, and physician or patient overall judgment were secondary objectives. Study population included 80 patients, 67 women and 13 men aged 66 ± 6 (SD) years. A significant improvement for all efficacy parameters was observed at all-time points in both groups. A significant difference in favor to clodronate in VAS for pain was observed 5 weeks after the last injection (−114.6 vs. −87.2 for clodronate and placebo group, respectively; p < 0.05). The improvements in Lequesne index, global KOA evaluation from both patients and investigators, and the WOMAC pain subscale were significantly greater in the clodronate group. The proportion of patients that did not require acetaminophen was significantly greater in the clodronate group (about 10 vs. 30 % for clodronate and placebo group, respectively; p < 0.05). IA 2 mg clodronate is associated with small and transient symptomatic and functional benefits and it is safe in KOA patients.
Literature
1.
go back to reference Herrero-Beaumont G, Roman-Blas JA, Castañeda S, Jimenez SA (2009) Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum 39:71–80PubMedCrossRef Herrero-Beaumont G, Roman-Blas JA, Castañeda S, Jimenez SA (2009) Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum 39:71–80PubMedCrossRef
2.
go back to reference Peat G, McCarney R, Croft P (2001) Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 60:91–97PubMedCentralPubMedCrossRef Peat G, McCarney R, Croft P (2001) Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 60:91–97PubMedCentralPubMedCrossRef
3.
go back to reference Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 64:465–474CrossRef Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 64:465–474CrossRef
4.
go back to reference Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18:476–499PubMedCrossRef Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18:476–499PubMedCrossRef
5.
go back to reference Herrero-Beaumont G, Roman-Blas JA, Largo R, Berenbaum F, Castaneda S (2011) Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. Ann Rheum Dis 70:1523–1525PubMedCrossRef Herrero-Beaumont G, Roman-Blas JA, Largo R, Berenbaum F, Castaneda S (2011) Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. Ann Rheum Dis 70:1523–1525PubMedCrossRef
6.
go back to reference Bush PG, Hall AC (2003) The volume and morphology of chondrocytes within non-degenerate and degenerate human articular cartilage. Osteoarthritis Cartilage 11:242–251PubMedCrossRef Bush PG, Hall AC (2003) The volume and morphology of chondrocytes within non-degenerate and degenerate human articular cartilage. Osteoarthritis Cartilage 11:242–251PubMedCrossRef
7.
go back to reference Goldring MB, Goldring SR (2010) Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann NY Acad Sci 1192:230–237PubMedCrossRef Goldring MB, Goldring SR (2010) Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann NY Acad Sci 1192:230–237PubMedCrossRef
8.
go back to reference Zhang ZM, Li ZC, Jiang LS, Jiang SD, Dai LY (2010) Micro-CT and mechanical evaluation of subchondral trabecular bone structure between postmenopausal women with osteoarthritis and osteoporosis. Osteoporos Int 21:1383–1390PubMedCrossRef Zhang ZM, Li ZC, Jiang LS, Jiang SD, Dai LY (2010) Micro-CT and mechanical evaluation of subchondral trabecular bone structure between postmenopausal women with osteoarthritis and osteoporosis. Osteoporos Int 21:1383–1390PubMedCrossRef
9.
go back to reference Karvonen RL, Miller PR, Nelson DA, Granda JL, Fernandez-Madrid F (1998) Periarticular osteoporosis in osteoarthritis of the knee. J Rheumatol 25:2187–2194PubMed Karvonen RL, Miller PR, Nelson DA, Granda JL, Fernandez-Madrid F (1998) Periarticular osteoporosis in osteoarthritis of the knee. J Rheumatol 25:2187–2194PubMed
10.
go back to reference Messent EA, Ward RJ, Tonkin CJ, Buckland-Wright C (2005) Cancellous bone differences between knees with early, definite and advanced joint space loss: a comparative quantitative macroradiographic study. Osteoarthritis Cartilage 13:39–47PubMedCrossRef Messent EA, Ward RJ, Tonkin CJ, Buckland-Wright C (2005) Cancellous bone differences between knees with early, definite and advanced joint space loss: a comparative quantitative macroradiographic study. Osteoarthritis Cartilage 13:39–47PubMedCrossRef
11.
go back to reference Davies-Tuck ML, Wluka AE, Wang Y et al (2009) The natural history of bone marrow lesions in community-based adults with no clinical knee osteoarthritis. Ann Rheum Dis 68:904–908PubMedCrossRef Davies-Tuck ML, Wluka AE, Wang Y et al (2009) The natural history of bone marrow lesions in community-based adults with no clinical knee osteoarthritis. Ann Rheum Dis 68:904–908PubMedCrossRef
12.
go back to reference Dore D, Quinn S, Ding C et al (2010) Subchondral bone and cartilage damage: a prospective study in older adults. Arthritis Rheum 62:1967–1973PubMed Dore D, Quinn S, Ding C et al (2010) Subchondral bone and cartilage damage: a prospective study in older adults. Arthritis Rheum 62:1967–1973PubMed
13.
go back to reference Bergman AG, Willen HK, Lindstrand AL, Pettersson HAT (1994) Osteoarthritis of the knee: correlation of subchondral MR signal abnormalities with histopathologic and radiographic features. Skeletal Radiol 23:445–448PubMedCrossRef Bergman AG, Willen HK, Lindstrand AL, Pettersson HAT (1994) Osteoarthritis of the knee: correlation of subchondral MR signal abnormalities with histopathologic and radiographic features. Skeletal Radiol 23:445–448PubMedCrossRef
14.
go back to reference Zanetti M, Bruder E, Romero J, Hodler J (2000) Bone marrow edema pattern in osteoarthritic knees: correlation between MR imaging and histologic findings. Radiology 215:835–840PubMedCrossRef Zanetti M, Bruder E, Romero J, Hodler J (2000) Bone marrow edema pattern in osteoarthritic knees: correlation between MR imaging and histologic findings. Radiology 215:835–840PubMedCrossRef
15.
go back to reference Hernandez-Molina G, Guermazi A, Niu J et al (2008) Central bone marrow lesions in symptomatic knee osteoarthritis and their relationship to anterior cruciate ligament tears and cartilage loss. Arthritis Rheum 58:130–136PubMedCentralPubMedCrossRef Hernandez-Molina G, Guermazi A, Niu J et al (2008) Central bone marrow lesions in symptomatic knee osteoarthritis and their relationship to anterior cruciate ligament tears and cartilage loss. Arthritis Rheum 58:130–136PubMedCentralPubMedCrossRef
16.
go back to reference Yusuf E, Kortekaas MC, Watt I, Huizinga TW, Kloppenburg M (2011) Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis 70:60–67PubMedCrossRef Yusuf E, Kortekaas MC, Watt I, Huizinga TW, Kloppenburg M (2011) Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis 70:60–67PubMedCrossRef
17.
go back to reference Karsdal MA, BayJensen AC, Lories RJ et al (2014) The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments ? Ann Rheum Dis 73:336–348PubMedCrossRef Karsdal MA, BayJensen AC, Lories RJ et al (2014) The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments ? Ann Rheum Dis 73:336–348PubMedCrossRef
18.
go back to reference Carbone LD, Nevitt MC, Wildy K et al (2004) The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 50:3516–3525PubMedCrossRef Carbone LD, Nevitt MC, Wildy K et al (2004) The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 50:3516–3525PubMedCrossRef
19.
go back to reference Muehleman C, Green J, Williams JM et al (2002) The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 10:226–233PubMedCrossRef Muehleman C, Green J, Williams JM et al (2002) The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 10:226–233PubMedCrossRef
20.
go back to reference Hayami T, Pickarski M, Wesolowski GA et al (2004) The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50:1193–1206PubMedCrossRef Hayami T, Pickarski M, Wesolowski GA et al (2004) The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50:1193–1206PubMedCrossRef
21.
go back to reference Funck-Brentano T, Lin H, Hay E et al (2012) Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PLoS One 7:e33543PubMedCentralPubMedCrossRef Funck-Brentano T, Lin H, Hay E et al (2012) Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PLoS One 7:e33543PubMedCentralPubMedCrossRef
22.
go back to reference Panahifar A, Maksymowych WP, Doschak MR (2012) Potential mechanism of alendronate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation. Osteoarthritis Cartilage 20:694–702PubMedCrossRef Panahifar A, Maksymowych WP, Doschak MR (2012) Potential mechanism of alendronate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation. Osteoarthritis Cartilage 20:694–702PubMedCrossRef
23.
go back to reference Teronen O, Heikkila P, Konttinen YT et al (1999) MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 878:453–465PubMedCrossRef Teronen O, Heikkila P, Konttinen YT et al (1999) MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 878:453–465PubMedCrossRef
24.
go back to reference Fujita T, Fujii Y, Okada SF, Miyauchi A, Takagi Y (2001) Analgesic effect of etidronate on degenerative joint disease. J Bone Miner Metab 19:251–256PubMedCrossRef Fujita T, Fujii Y, Okada SF, Miyauchi A, Takagi Y (2001) Analgesic effect of etidronate on degenerative joint disease. J Bone Miner Metab 19:251–256PubMedCrossRef
25.
go back to reference Neogi T, Nevitt MC, Ensrud KE, Bauer D, Felson DT (2008) The effect of alendronate on progression of spinal osteophytes and disc space narrowing. Ann Rheum Dis 67:1427–1430PubMedCrossRef Neogi T, Nevitt MC, Ensrud KE, Bauer D, Felson DT (2008) The effect of alendronate on progression of spinal osteophytes and disc space narrowing. Ann Rheum Dis 67:1427–1430PubMedCrossRef
26.
go back to reference Spector TD, Conaghan PG, Buckland-Wright JC et al (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther 7:R625–R633PubMedCentralPubMedCrossRef Spector TD, Conaghan PG, Buckland-Wright JC et al (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther 7:R625–R633PubMedCentralPubMedCrossRef
27.
go back to reference Bingham CO, Buckland-Wright JC, Garnero P et al (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year Multinational Knee Osteoarthritis Structural Arthritis Study. Arthritis Rheum 54:3494–3507PubMedCrossRef Bingham CO, Buckland-Wright JC, Garnero P et al (2006) Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year Multinational Knee Osteoarthritis Structural Arthritis Study. Arthritis Rheum 54:3494–3507PubMedCrossRef
28.
go back to reference Laslett LL, Dore DA, Quinn SJ et al (2012) Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 71:1322–1328PubMedCrossRef Laslett LL, Dore DA, Quinn SJ et al (2012) Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 71:1322–1328PubMedCrossRef
29.
go back to reference Laslett LL, Kingsbury SR, Hensor EM, Bowes MA, Conaghan PG (2014) Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. Ann Rheum Dis 73:824–830PubMedCrossRef Laslett LL, Kingsbury SR, Hensor EM, Bowes MA, Conaghan PG (2014) Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. Ann Rheum Dis 73:824–830PubMedCrossRef
31.
go back to reference Rossini M, Viapiana O, Ramonda R et al (2009) Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid. Rheumatology 48:773–778PubMedCrossRef Rossini M, Viapiana O, Ramonda R et al (2009) Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid. Rheumatology 48:773–778PubMedCrossRef
32.
go back to reference Jordan KM, Arden NK, Doherty M et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145–1155PubMedCentralPubMedCrossRef Jordan KM, Arden NK, Doherty M et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145–1155PubMedCentralPubMedCrossRef
33.
go back to reference Rutijes AWS, Juni P, da Costa BR et al (2012) Viscosupplementation for Ostearthritis of the knee: a systematic review and meta-analysis. Ann Int Med 157:180–191CrossRef Rutijes AWS, Juni P, da Costa BR et al (2012) Viscosupplementation for Ostearthritis of the knee: a systematic review and meta-analysis. Ann Int Med 157:180–191CrossRef
34.
go back to reference Bellamy N, Campbell J, Robinson V et al (2006) Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2:CD005328 Bellamy N, Campbell J, Robinson V et al (2006) Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2:CD005328
35.
go back to reference Jørgensen A, Stengaard-Pedersen K, Simonsen O et al (2010) Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year. Ann Rheum Dis 69:1097–1102PubMedCrossRef Jørgensen A, Stengaard-Pedersen K, Simonsen O et al (2010) Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year. Ann Rheum Dis 69:1097–1102PubMedCrossRef
36.
go back to reference Lundsgaard C, Dufour N, Fallentin E, Winkel P, Gluud C (2008) Intra-articular sodium hyaluronate 2 mL versus physiological saline 20 mL versus physiological saline 2 mL for painful knee osteoarthritis: a randomized clinical trial. Scand J Rheumatol 37:142–150PubMedCrossRef Lundsgaard C, Dufour N, Fallentin E, Winkel P, Gluud C (2008) Intra-articular sodium hyaluronate 2 mL versus physiological saline 20 mL versus physiological saline 2 mL for painful knee osteoarthritis: a randomized clinical trial. Scand J Rheumatol 37:142–150PubMedCrossRef
37.
go back to reference Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M (2008) The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 67:1716–1723PubMedCrossRef Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M (2008) The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 67:1716–1723PubMedCrossRef
38.
go back to reference Altman R, Asch E, Bloch D et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29:1039–1049PubMedCrossRef Altman R, Asch E, Bloch D et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29:1039–1049PubMedCrossRef
39.
go back to reference Kellgren MJ (1963) The epidemiology of chronic rheumatism: atlas of standard radiographs, 2nd edn. Blackwell Scientific, Oxford, UK Kellgren MJ (1963) The epidemiology of chronic rheumatism: atlas of standard radiographs, 2nd edn. Blackwell Scientific, Oxford, UK
40.
go back to reference Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172PubMedCrossRef Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172PubMedCrossRef
41.
go back to reference Bellamy N, Buchanan WW, Goldsmith CH et al (1998) Validation Study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840 Bellamy N, Buchanan WW, Goldsmith CH et al (1998) Validation Study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840
42.
go back to reference Lequesne M, Méry C, Samson M et al (1987) Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatol 65(Suppl):85–89CrossRef Lequesne M, Méry C, Samson M et al (1987) Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatol 65(Suppl):85–89CrossRef
43.
go back to reference Ranstam J, Turkiewicz A, Boonen S et al (2012) Alternative analyses for handling incomplete follow-up in the intention-to-treat analysis: the randomized controlled trial of balloon kyphoplasty versus non-surgical care for vertebral compression fracture (FREE). BMC Med Res Methodol 24(12):35CrossRef Ranstam J, Turkiewicz A, Boonen S et al (2012) Alternative analyses for handling incomplete follow-up in the intention-to-treat analysis: the randomized controlled trial of balloon kyphoplasty versus non-surgical care for vertebral compression fracture (FREE). BMC Med Res Methodol 24(12):35CrossRef
44.
go back to reference Wang CT, Lin J, Chang CJ, Lin YT, Hou SM (2004) Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am 86-A:538–545PubMed Wang CT, Lin J, Chang CJ, Lin YT, Hou SM (2004) Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am 86-A:538–545PubMed
45.
go back to reference Bellamy N, Campbell J, Robinson V et al (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2:CD005321 Bellamy N, Campbell J, Robinson V et al (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2:CD005321
46.
go back to reference Reichenbach S, Blank S, Rutjes AW et al (2007) Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 57:1410–1418PubMedCrossRef Reichenbach S, Blank S, Rutjes AW et al (2007) Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum 57:1410–1418PubMedCrossRef
47.
go back to reference Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE (2011) Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis—meta-analysis. Osteoarthritis Cartilage 19:611–619PubMedCrossRef Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE (2011) Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis—meta-analysis. Osteoarthritis Cartilage 19:611–619PubMedCrossRef
48.
go back to reference Arrich J, Piribauer F, Mad P et al (2005) Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 172:1039–1043PubMedCentralPubMedCrossRef Arrich J, Piribauer F, Mad P et al (2005) Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 172:1039–1043PubMedCentralPubMedCrossRef
49.
go back to reference Medina JM, Thomas A, Denegar CR (2006) Knee osteoarthritis: should your patient opt for hyaluronic acid injection? J Fam Pract 55:669–675PubMed Medina JM, Thomas A, Denegar CR (2006) Knee osteoarthritis: should your patient opt for hyaluronic acid injection? J Fam Pract 55:669–675PubMed
50.
go back to reference Lo GH, LaValley M, McAlindon T, Felson DT (2003) Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 290:3115–3121PubMedCrossRef Lo GH, LaValley M, McAlindon T, Felson DT (2003) Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 290:3115–3121PubMedCrossRef
51.
go back to reference Zhen G, Wen C, Jia X et al (2013) Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nature Med 19(6):704–712. doi:10.1038/nm.3143 Zhen G, Wen C, Jia X et al (2013) Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nature Med 19(6):704–712. doi:10.​1038/​nm.​3143
52.
go back to reference Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201–2210PubMedCrossRef Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ (2001) The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201–2210PubMedCrossRef
53.
go back to reference Rossini M, Adami S, Viapiana O et al (2012) Long-term effects of amino-bisphosphonates on circulating γδ T cells. Calcif Tissue Int 91:395–399PubMedCrossRef Rossini M, Adami S, Viapiana O et al (2012) Long-term effects of amino-bisphosphonates on circulating γδ T cells. Calcif Tissue Int 91:395–399PubMedCrossRef
54.
go back to reference Rossini M, Adami S, Viapiana O et al (2013) Acute phase response after zoledronic acid is associated with long-term effects on white blood cells. Calcif Tissue Int 93:249–252PubMedCrossRef Rossini M, Adami S, Viapiana O et al (2013) Acute phase response after zoledronic acid is associated with long-term effects on white blood cells. Calcif Tissue Int 93:249–252PubMedCrossRef
55.
go back to reference Barrera P, Blom A, Van Lent PL et al (2000) TI: synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 43:1951–1959PubMedCrossRef Barrera P, Blom A, Van Lent PL et al (2000) TI: synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 43:1951–1959PubMedCrossRef
56.
go back to reference Cinar BM, Ozkoc G, Bolat F et al (2014) Intra articular zoledronic acid in rat osteoarthritis model: significant reduced synovitis may indicate chondroprotective effect. Knee Surg Sports Traumatol Arthrosc [Epub ahead of print] Cinar BM, Ozkoc G, Bolat F et al (2014) Intra articular zoledronic acid in rat osteoarthritis model: significant reduced synovitis may indicate chondroprotective effect. Knee Surg Sports Traumatol Arthrosc [Epub ahead of print]
57.
go back to reference Sagar DR, Ashraf S, Xu L et al (2013) Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis. Ann Rheum Dis [Epub ahead of print] Sagar DR, Ashraf S, Xu L et al (2013) Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis. Ann Rheum Dis [Epub ahead of print]
58.
go back to reference Varenna M, Adami S, Rossini M et al (2013) Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology 52:534–542PubMedCrossRef Varenna M, Adami S, Rossini M et al (2013) Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology 52:534–542PubMedCrossRef
59.
go back to reference Yanow J, Pappagallo M, Pillai L (2008) Complex regional pain syndrome (CRPS/RSD) and neuropathic pain: role of intravenous bisphosphonates as analgesics. ScientificWorldJournal 8:229–236PubMedCrossRef Yanow J, Pappagallo M, Pillai L (2008) Complex regional pain syndrome (CRPS/RSD) and neuropathic pain: role of intravenous bisphosphonates as analgesics. ScientificWorldJournal 8:229–236PubMedCrossRef
60.
go back to reference Dehghani F, Conrad A, Kohl A, Korf HW, Hailer NP (2004) Clodronate inhibits the secretion of proinflammatory cytokines and NO by isolated microglial cells and reduces the number of proliferating glial cells in excitotoxically injured organotypic hippocampa slice cultures. Exp Neurol 189:241–251PubMedCrossRef Dehghani F, Conrad A, Kohl A, Korf HW, Hailer NP (2004) Clodronate inhibits the secretion of proinflammatory cytokines and NO by isolated microglial cells and reduces the number of proliferating glial cells in excitotoxically injured organotypic hippocampa slice cultures. Exp Neurol 189:241–251PubMedCrossRef
61.
go back to reference Reginster JY, Badurski J, Bellamy N et al (2013) Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 72:179–186PubMedCentralPubMedCrossRef Reginster JY, Badurski J, Bellamy N et al (2013) Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 72:179–186PubMedCentralPubMedCrossRef
62.
go back to reference Fleisch H (2007) Introduction to bisphosphonates, History and functional mechanisms. Orthopade 36:103–109PubMedCrossRef Fleisch H (2007) Introduction to bisphosphonates, History and functional mechanisms. Orthopade 36:103–109PubMedCrossRef
63.
go back to reference Rose K, Finger IE, Ferenz KB (2011) Interaction of clodronate with fibroblast growth factor 2 reduces FGF2-activity in endothelial cells. Biomed Pharmacother 65:46–51PubMedCrossRef Rose K, Finger IE, Ferenz KB (2011) Interaction of clodronate with fibroblast growth factor 2 reduces FGF2-activity in endothelial cells. Biomed Pharmacother 65:46–51PubMedCrossRef
64.
go back to reference Gomez-Barrena E, Lindroos L, Ceponis A et al (2006) Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. Clin Exp Rheumatol 24:622–628PubMed Gomez-Barrena E, Lindroos L, Ceponis A et al (2006) Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. Clin Exp Rheumatol 24:622–628PubMed
65.
go back to reference Nancollas GH, Tang R, Phipps RJ et al (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627PubMedCrossRef Nancollas GH, Tang R, Phipps RJ et al (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627PubMedCrossRef
Metadata
Title
Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial
Authors
Maurizio Rossini
Silvano Adami
Elena Fracassi
Ombretta Viapiana
Giovanni Orsolini
Maria Rosaria Povino
Luca Idolazzi
Davide Gatti
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3100-5

Other articles of this Issue 2/2015

Rheumatology International 2/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.